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Patients with chronic granulomatous disease are predisposed to fungal infections and are therefore routinely prescribed antifungal
prophylaxis. We report a case where acremonium was responsible for causing a cutaneous infection (mycetoma) despite antifungal
prophylaxis. Treatmentwith voriconazolewas initiated and the infection gradually resolved.This case highlights the need for careful
clinical follow-up and thorough investigation of patients who have a neutrophil immunodeficiency.
1. Introduction
Chronic granulomatous disease (CGD) is a primary immun-
odeficiency syndrome characterised by impaired neutrophil
superoxide generation and microbial killing. It is a rare con-
dition, with one affected case per 200,000–250,000 live births
[1]. Autosomal recessive and X-linked forms occur with the
latter accounting for approximately two-thirds of cases. In the
X-linked form, mutations in the CYBB gene result in a loss of
gp91phox function. As a result, NADPH oxidase activation is
reduced and an important killing mechanism for neutrophils
is defective.
CGD patients are susceptible to infection from a range
of microorganisms, but bacteria and fungi predominate. The
most common cause of severe fungal infections is aspergillus
[2]. Of nonaspergillus fungal infections inCGD, acremonium
contributes just less than 3%of the reported cases [3].Herewe
report what we believe is the first occurrence of a cutaneous
infection due to acremonium in a young adult with X-linked
CGD.
2. Case Presentation
Our patient was diagnosed with CGD in his first year of
life as a result of his older brother being diagnosed with
the same condition. The diagnosis was made on the basis of
a nitroblue-tetrazolium (NBT) test but not confirmed with
molecular genetics. He had previously experienced episodes
of pneumonia, colitis, perianal abscesses with fistulae, and
other bacterial abscesses as complications of his CGD.
He presented at 20 years old with a subcutaneous swelling
over the medial aspect of his left scapular. At this point
his regular medications were itraconazole 200mg and co-
trimoxazole 960mg (both once daily) which were prescribed
for antimicrobial prophylaxis. Itraconazole levels at the time
of presentation measured 0.51mg/L which are normally
deemed adequate for prophylaxis (but not treatment).
The swellingwas fluctuant andmildly tender. An infective
aetiology was suspected and therefore a diagnostic aspirate
was performed. This yielded nonoffensive blood stained pus,
and samples were sent for routine microscopy and culture.
He was prescribed one week of empirical antibiotics (co-
amoxiclav 625mg tds and clindamycin 300mg qds). In the
laboratory, pus cells were demonstrated on microscopy but
standard cultures were negative.
One week later the patient’s swelling had increased in
size (Figure 1(a)). A second aspirate was performed and
both this and the previous sample were then cultured on
Sabouraud agar. This revealed a filamentous fungus that was
later confirmed by the reference laboratory to be Acremo-
nium spp. Ribosomal 16S had also been performed but did
not identify a causative organism. Three weeks later the
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Figure 1: (a) Appearances of the closed abscess after one week of antibiotics (note central puncture site from previous diagnostic aspirate).
(b) Proliferating granulation tissue, four weeks after top images were taken. (c) Healing ulcer, four months after the top images were taken.
acremonium was reported to be sensitive to itraconazole,
voriconazole, posaconazole, and amphotericin B but resistant
to fluconazole.
Following confirmation that the infection was fungal in
nature, itraconazole had been stopped and voriconazole com-
menced. Levels were taken at 8 and 30 days into treatment
and found to be 3.91 and 3.97mg/L, respectively, indicating
adequate levels for treatment. A CT scan was performed to
exclude the possibility that the infection was tracking from
an internal source and a bronchoscopy with washing was
performed to exclude a pulmonary origin for the infection.
These investigations lead us to conclude that the infectionwas
limited to the skin.
The closed abscess spontaneously discharged and gran-
ulation tissue proliferated through the exit site (Figure 1(b)).
A short course of low dose prednisolone was used alongside
voriconazole to help this resolve without surgical interven-
tion. After 8weeks of treatmentwith voriconazole, the patient
was recommenced on itraconazole (at the increased dose
of 200mg twice daily). Eventually the granulation tissue
resorbed and healthy skin started to close over the ulcerated
area (Figure 1(c)).
3. Discussion
Acremonium spp. have been reported to cause pulmonary
infection in children with CGD on two previous occasions
[4, 5]. To our knowledge, this is the first instance where an
adult withCGDhas been infectedwith acremoniumorwhere
the skin has been the main site of infection.
Acremonium spp. are filamentous moulds which are
widespread in environment materials such as soil or dead
plant matter. They are a recognised but rare source of infec-
tion in humans. Cutaneous infections are one of the most
common presentations in the immunocompetent host [6].
Mycetoma can formwhen localised trauma allows the fungus
to penetrate the skin’s barrier. In the developing world this
would typically occur as a result ofwalking barefoot.However
such infections are also recognised to occur without a history
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of trauma, as in this case. Invasive acremonium infections are
more pertinent to the immunocompromised host, although
the majority of reported cases relate to immunodeficiency
that is secondary to medication, malignancy, and transplan-
tation.
The available literature suggests that patients with CGD
rarely develop infections due to acremonium. In the only
reported cases of this occurring, the lung has been the
primary site of infection. In Brazil, an infant was diagnosed
with an acremonium lung infection after developing a hilar
pneumonia that failed to respond to antibiotics [5]. Oral itra-
conazole (at 10mg/kg/day) was used for treatment, with both
clinical and radiological improvement being seen within 6
weeks. In a case report from 1984, a 15-year-old boywithCGD
presentedwith suspected pneumonia and failed to respond to
antibiotics [4]. He responded clinically but not radiologically
to treatment with amphotericin and ketoconazole. This may
account for why his treatment was continued for over 3
months.
When infections with moulds do occur in CGD patients,
the mortality is high (16/49 cases, 32.7%) [3]. This case
highlights the need for clinical immunologists to ensure
that antifungal prophylaxis is maintained in patients with
CGD. An increasing proportion of patients with CGD are
being treated definitively with stem cell transplantation.
Gene therapy is also a potential treatment for CGD patients
and research into this technique is ongoing. The fact that
breakthrough fungal infections can occur in adult life in
untransplanted patients is a reminder of why parents are
encouraged to choose transplantation for their childrenwhile
they are young and free from infection.
Finally, this case highlights the importance of good
communication between microbiology and immunology
departments when sending samples from immunodeficient
patients. Microbiology laboratories should be vigilant to the
possibility of fungal and other fastidious infections when
deciding how to process samples from immunodeficient
patients.
4. Conclusion
Acremonium is a rare cause of infection, with patterns of
infection being different between immunocompetent and
immunocompromised hosts. While patients with CGD are
recognised to be at increased risk of fungal infections,
infections with acremonium are highly unusual and to
our knowledge a case of acremonium causing a cutaneous
infection has never been reported in CGD. The fungus was
sensitive to itraconazole, yet the infection occurred while the
patient was taking itraconazole prophylaxis. The infection
improved following 8 weeks of treatment with voriconazole,
and no recurrence has been observed in the subsequent 6
months.
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